TGD001 - Scientific Publications

Novel von willebrand factor targeting thrombolytic TGD001 is safe and well tolerated in a phase 1 first-in-human trial

Marie Scully, Spero Cataland, Paul Coppo, Paul Knoebl, Paul Brinkkoetter, Javier de la Rubia, Marielle Klein Hesselink, Josefin-Beate Holz, Flora Peyvandi

Novel von willebrand factor targeting thrombolytic TGD001 is effective in diverse thrombotic models, demonstrating its potential as a universal thrombolytic

Volker Laux, Claudia Tersteeg, Sarah Vandelanotte, Sarah Mc Fie, Danielle Versluis, Filio Petsini, Anne-Sophie Delmote, Kristof Vercruysse, Simon de Meyer, Karen Vanhoorelbeke, Steven de Maat

TGD001, a VWF-targeted thrombolytic, is safe and effective in animal models for the treatment of thrombotic thrombocytopenic purpura.

C. Tersteeg¹, S. Mc Fie², D. Versluis², A. Delmote¹, K. Vercruysse², K. Wosikowski², G. van ‘t Klooster², K. Vanhoorelbeke¹, S. de Maat².
¹KU Leuven Campus Kulak, Kortrijk, Belgium
²TargED Biopharmaceuticals B.V., Utrecht, the Netherlands

VWF-targeted thrombolysis to overcome rh-tPA resistance in experimental murine ischemic stroke models.

van Moorsel, M. V. A., de Maat, S., Vercruysse, K., van Leeuwen, E. M., Jacqmarcq, C., Bonnard, T., Vivien, D., van der Worp, H. B., Dijkhuizen, R. M., & Maas, C. (2022). Blood, The Journal of the American Society of Hematology, 140(26), pp.2844-2848.

Microlyse: a thrombolytic agent that targets VWF for clearance of microvascular thrombosis.

de Maat, S., Clark, C. C., Barendrecht, A. D., Smits, S., van Kleef, N. D., el Otmani, H., Waning, M., van Moorsel, M., Szardenings, M., Delaroque, N., Vercruysse, K., Urbanus, R. T., Sebastian, S., Lenting, P. J., Hagemeyer, C., Renné, T., Vanhoorelbeke, K., Tersteeg, C., & Maas, C. (2022). Blood, The Journal of the American Society of Hematology, 139(4), pp.597-607.